How Will You Shape
the Future of Oncology Care?
Collaboration is the catalyst for progress. Together, we can revolutionize cancer care with non-invasive, cost-effective diagnostics.
At PanGIA, we’re transforming how cancer is diagnosed with non-invasive true liquid biopsy solutions powered by AI/ML.
Our novel chemistry and easily collected urine specimens deliver earlier answers, better outcomes, and measurable value for patients, clinicians, and stakeholders.
Join us in pioneering the next generation of oncology diagnostics.
Proven Impact:
Transforming Care Globally
Delivering life-saving solutions to real-world settings.
In select international markets, PanGIA’s prostate assay has achieved high sensitivity rates¹,², delivering earlier diagnoses with true liquid biopsies without invasive procedures.
Our solutions leverage AI/ML to analyze novel chemistry in urine, improving cancer detection, patient outcomes, and clinician workflows worldwide.
What could this proven innovation mean for patients and clinicians in the U.S.?
Innovating for
Tomorrow’s Toughest Challenges
Expanding diagnostic capabilities for greater impact.
By leveraging AI/ML-powered diagnostics with true liquid biopsies, we’re creating tools that identify key biological patterns in easily collected urine samples, enabling earlier, more precise detection³.
Together, we can close critical diagnostic gaps and bring new tools to the patients who need them most.
Unlocking Opportunities
in a $249 Billion Market
Meeting the growing global demand for oncology diagnostics.
PanGIA’s non-invasive platform, powered by AI and novel chemistry, offers a high-impact alternative to traditional diagnostics—one that reduces costs and improves patient experience.
What role could we play—together—in transforming this rapidly evolving market?
Clarity Through Data:
Proven Metrics for Partners
Building confidence through transparency.
The PanGIA Prostate Assay has demonstrated high sensitivity and specificity ¹,², outperforming competitors and providing reliable results.
Additional metrics include:
- Adoption rates in global markets.
- Projected U.S. market growth.
- Cost-savings for payers and providers.
Making Access Seamless
for Payers and Providers
Simplifying reimbursement for greater adoption.
PanGIA provides resources to streamline the process, ensuring stakeholders have the tools to integrate our true liquid biopsy solutions efficiently.
What if reimbursement didn’t have to be a barrier to innovation?
What Partners Like You
Need to Know.
PanGIA combines AI/ML-driven diagnostics with non-invasive urine-based true liquid biopsy testing, delivering earlier, more accurate cancer detection. Unlike traditional biopsies, our true liquid biopsy platform minimizes complications and increases patient compliance. PanGIA’s initial clinical data reflects strong sensitivity and specificity—outperforming many current diagnostic standards.
Our prostate cancer assay is transforming care in select international markets, where it is trusted by clinicians for its accuracy and ease of integration¹,². Building on international adoption, we are advancing additional assays for future availability.
Currently, our validated solution focuses on prostate cancer. Validation studies for additional cancers, including pancreatic, ovarian, and breast, are scheduled to begin in early 2024³.
- For Investors: Positioned to scale within the $249 billion oncology diagnostics market, projected to grow significantly by 2028⁴.
- For Clinicians: Simplifies workflows with non-invasive, fast-turnaround diagnostics.
- For Payers: Reduces unnecessary procedures and associated costs, offering a cost-effective solution for early cancer detection.
Sign up for regular updates on pipeline developments, FDA progress, and market insights. Sign up here.
Ready to Shape the
Future of Oncology Care?
Collaboration is key to innovation.
Whether you’re an investor or clinician, PanGIA offers a unique opportunity to deliver better outcomes and measurable value.
Let’s build a future where earlier detection and better care are the new standard.
References:
- Lim FB, Lei T, Fernandez G, et al. A Colorimetric Chemical Tongue Detects and Distinguishes Between Multiple Analytes. Analyst. 2022;147(23):5283-5292. doi:10.1039/D2AN01615J.
- PanGIA Biotech. Clinical Validation of Prostate Assay. Internal Data. 2024.
- PanGIA Biotech. 2024 Executive Summary. Non-confidential.
- International Agency for Research on Cancer. Global Cancer Statistics. World Health Organization; 2022.